ICP
VIR icon

Indus Capital Partners’s Vir Biotechnology VIR Stock Holding History

Indus Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-87,638
Closed -$3M – 55
2020
Q1 		$3M Sell
87,638
-594,298
-87% -$16M 0.51% 34
2019
Q4 		$8.57M Buy
+681,936
New +$9.14M 1.68% 21

Other funds holding VIR

SB Investment Advisers (UK)
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.28B AUM 16.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Iconiq Capital
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Indus Capital Partners's VIR Position: Q2 2020 in Review

Indus Capital Partners sold out of Vir Biotechnology (VIR) in Q2 2020, closing a stake of 87,638 shares — an estimated $3M sold.

Indus Capital Partners first reported a position in VIR in Q4 2019 and held it in 2 quarters. The position peaked at $8.57M in Q4 2019. 112 funds tracked by Wall St. Rank hold VIR as of Q2 2020.

  • Indus Capital Partners reported no remaining Vir Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Indus Capital Partners sold 87,638 Vir Biotechnology shares in Q2 2020, an estimated $3M.
  • Indus Capital Partners first reported a position in Vir Biotechnology in Q4 2019 and held it in 2 quarters.
  • Indus Capital Partners's Vir Biotechnology position peaked at $8.57M in Q4 2019.
  • 112 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2020.

Based on Indus Capital Partners's 13F filing for Q2 2020, filed 13 Aug 2020.